Gentian News: Turbidimetric Cardiac Immunoassay

17. Dec 2019 | 2 min read

Gentian News: Turbidimetric Cardiac Immunoassay

Gentian has been granted a funding of 14M NOK distributed over 4 years for our project “Development of a rapid, affordable, high-throughput cardiac test” through the Research Council of Norway’s program “Innovation Project for the Industrial Sector

 

R&D objectives

The primary objective for the R&D activities in this project is to further develop and optimise Gentian’s highly sensitive and robust technology to develop a cardiac immunoassay for turbidimetric, fast, cost-effective and high volume clinical analysers, validated by solid clinical studies.

Torsten Knüttel, VP Research & Development, Gentian AS says: Within our cardiac biomarker project we aim to push the boundaries of particle-enhanced turbidimetric technology, and it is very positive to see that with this funding, the Research Council of Norway recognises Gentian’s expertise and leading position within this field.

Gentian has taken the approach of further innovating our existing technologies to allow measurement of low-concentration marker tests on existing high-throughput, low-cost clinical chemistry analysers, which are already the golden standard in all small and central laboratories.

 

Addressing the global challenge of heart failure and cardiac dysfunction

More than 26 million people worldwide are suffering from heart failure (HF) and cardiac dysfunction. The global burden of HF and cardiac dysfunction is increasing rapidly with the aging of the population, and it is one of the main global public health problems. A rapid, cost-effective test for heart failure will help address this issue. Hilja Ibert, CEO Gentian Diagnostics elaborates: “This project is an example on how Gentian focuses to improve diagnostic efficiency, by which we mean that we convert existing diagnostic tests to faster, less expensive and more efficient platforms. We are very pleased that Research Council of Norway see the potential in our innovations”.

 

The Research Council of Norway

The Research Council of Norway works to promote research and innovation of high quality and relevance and to generate knowledge in priority areas to enable Norway to deal with key challenges to society and the business sector.

 

You may also read


Collaboration Proposal - COVID-19

Apr 03, 2020

Collaboration Proposal - COVID-19

We at Gentian AS believe it is the duty of all companies in the health industry to help combat the ongoing..

Statement to Customers on COVID-19 Concerns

Mar 13, 2020

Statement to Customers on COVID-19 Concerns

At Gentian, the health and safety of our employees, as well as our customers and partners, is of primary..

New article about calprotectin in Scientific Reports

Mar 11, 2020

New article about calprotectin in Scientific Reports

Calprotectin, a new biomarker for diagnosis of acute respiratory infections*